Tarsus Pharmaceuticals, Inc.

NASDAQ
TARS
Stock
Yield per half year: -13.45%
Dividend yield: 0%
Sector: Healthcare

42.98 $

0 $ +0%
21.54 $
56.94 $

Min/max per year

Share chart Tarsus Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., биофармацевтическая компания на клинической стадии, специализируется на разработке и коммерциализации новых терапевтических кандидатов для офтальмологических состояний. Его ведущим кандидатом в продукт является TP-03, новый терапевтический препарат, который находится в фазе IIb / III для лечения блефарита, вызванного заражением клещами Demodex, а также для лечения болезни мейбомиевых желез. Компания также разрабатывает TP-04 для лечения купероза; и TP-05 для профилактики Лайма и снижения заболеваемости малярией. Tarsus Pharmaceuticals, Inc.

more details
была зарегистрирована в 2016 году, ее штаб-квартира находится в Ирвине, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2020-10-16
ISIN US87650L1035
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Change price per day: +0% (42.98)
Change price per week: -4.51% (45.01)
Change price per month: -13.99% (49.97)
Change price per 3 month: -5.62% (45.54)
Change price per half year: -13.45% (49.66)
Change price per year: +22.76% (35.01)
Change price per 3 year: +209.21% (13.9)
Change price per year to date: -18.77% (52.91)
All parameters

Grade

Underestimation
Title Value Grade
P/S 11.38 1
P/BV 9.27 1
P/E 0 0
Efficiency
Title Value Grade
ROA, % -35.97 0
ROE, % -54.83 0
ROIC, % -25.09 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.6804 10
Debt/Ratio 0.1922 10
Debt/Equity 0.679 9
Growth impulse
Title Value Grade
Yield Revenue, % 447.76 10
Yield Ebitda, % 295.84 10
Yield EPS, % -28.87 0
More

Main owners

Institutions Volume Share, %
RTW Investments LP 3 152 341 9.21
Blackrock Inc. 2 516 139 7.35
Cormorant Asset Management, LP 2 221 422 6.49
Tang Capital Management, LLC 2 204 797 6.44
Morgan Stanley 1 957 688 5.72
COWEN AND COMPANY, LLC 1 911 399 5.59
Frazier Life Sciences Management, L.P. 1 787 527 5.22
Vivo Capital, LLC 1 784 006 5.21
Vanguard Group Inc 1 595 501 4.66
Perceptive Advisors LLC 1 296 416 3.79

Contained in ETF

ETFShare, %Profitability for 1 year, %Commission, %
Future Tech ETF 0.12645 426.34 0.35
Principal Healthcare Innovators ETF 0.12645 618.5 0.35
iShares Morningstar Small-Cap Growth ETF 0.02659 595.05 0.06
iShares Morningstar Small-Cap ETF 0.01793 391.25 0.25
iShares Morningstar Small-Cap Value ETF 0.00907 187.77 0.06
0.06443.780.21

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Bobak R. Azamian M.D. Co-Founder, President, CEO & Chairman 962.08k
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 486.67k 1968 (57 years)
Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary 619.09k 1978 (47 years)
Mr. David Nakasone Head of Investor Relations N/A
Mr. Matthew Rossen M.B.A. Vice President of Marketing N/A 1978 (47 years)
Dr. Elizabeth Yeu Lin M.D. Chief Medical Advisor & Director 286k 1978 (47 years)
Ms. Adrienne Kemp Senior Director of Corporate Communications N/A
Mr. Jeffrey S. Farrow CFO & Chief Strategy Officer N/A 1962 (63 years)
Mr. Scott Youmans Vice President of Sales N/A
Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer 578.9k 1977 (48 years)

About company

Address: United States, Irvine, 15440 Laguna Canyon Road - Open in google maps, Open in yandex maps
Website: http://www.tarsusrx.com